Tempus AI shares have fallen roughly 15% over the past year and about 4% year-to-date, even as the company reports strong revenue growth and expands its AI-powered precision medicine platform. In the most recent first quarter, revenue grew 36% year-over-year to $348.1 million, with its diagnostics business up 35% to $261.1 million and its Data and Applications segment up 40.5% to $87 million. Adjusted EBITDA loss narrowed to $2.8 million from $16.2 million in the prior quarter, and management expects positive adjusted EBITDA of $65 million in 2026. Wall Street analysts have a moderately bullish consensus, with an average price target of $65.62 implying 16% upside from current levels.
AstraZeneca PLC
Bristol-Myers Squibb Company
Gilead Sciences Inc
GSK plc
Merck & Company IncTempus AI, Inc. Class A Common StockStrong revenue growth, narrowing losses, and positive EBITDA outlook; analysts see 16% upside